Literature DB >> 10147236

Pharmacoeconomic studies on antibiotics: current controversies.

S R Norrby1.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 10147236     DOI： 10.2165/00019053-199405040-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  9 in total

1.  Evaluation of new anti-infective drugs for the treatment of acute suppurative arthritis in children. Infectious Diseases Society of America and the Food and Drug Administration.

Authors:  J D Nelson; C Norden; J T Mader; G B Calandra
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079

Review 2.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

3.  Imipenem/cilastatin versus gentamicin/clindamycin: a cost effectiveness study.

Authors:  S R Norrby; M Eriksson; E Ottosson
Journal:  Scand J Infect Dis       Date:  1986

Review 4.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 5.  Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections.

Authors:  P Benfield; P Chrisp
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

6.  Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci.

Authors:  D Stamboulian; P Bonvehi; C Arevalo; R Bologna; I Cassetti; V Scilingo; E Efron
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

7.  Therapy of acute and chronic gram-negative osteomyelitis with ciprofloxacin. Report from a Swedish Study Group.

Authors: 
Journal:  J Antimicrob Chemother       Date:  1988-08       Impact factor: 5.790

Review 8.  Ciprofloxacin in the treatment of acute and chronic osteomyelitis: a review.

Authors:  S R Norrby
Journal:  Scand J Infect Dis Suppl       Date:  1989

9.  Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.

Authors:  H W Pfister; V Preac-Mursic; B Wilske; E Schielke; F Sörgel; K M Einhäupl
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226
  9 in total
  5 in total

1.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

2.  Cost comparison of antibacterial therapies for serious infections. A New Zealand 3-hospital study.

Authors:  W G Scott; H M Scott; S Henderson; A Inder; J Sanders; R Spearing; C McArthur; J Judson; B Baker; P Hicks; P Cotterell
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

Review 3.  Antimicrobial drug utilisation in hospitals in Italy and other European countries.

Authors:  L Guglielmo; R Leone; U Moretti; A Conforti; G P Velo
Journal:  Infection       Date:  1994       Impact factor: 3.553

Review 4.  Antibacterial use in community practice: assessing quantity, indications and appropriateness, and relationship to the development of antibacterial resistance.

Authors:  A G Carrie; G G Zhanel
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 5.  Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.

Authors:  A Adu; C L Armour
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.